Azenta Reports Mixed Q1 Results, Authorizes $250M Share Repurchase, Finalizes B Medical Systems Sale
AZTA sits 48% above its 52-week low of $23.91.
Summary
Azenta, Inc. reported mixed first-quarter fiscal 2026 results with declining non-GAAP EPS and Adjusted EBITDA, but reaffirmed full-year guidance and authorized a new $250 million share repurchase program. The company also finalized the definitive agreement for the sale of its B Medical Systems business.
Key Events · Earnings and Guidance · AZTA
-
Q1 Fiscal 2026 Financial Results
Revenue was $149 million, up 1% year-over-year, though organic revenue declined 1%. Diluted EPS from continuing operations improved to ($0.11) from ($0.16) year-over-year, but Non-GAAP Diluted EPS decreased to $0.09 from $0.12. Adjusted EBITDA declined to $13 million from $16 million, and gross margin fell to 42.9%.
-
New Share Repurchase Program Authorized
The Board of Directors approved a new share repurchase program authorizing the repurchase of up to $250 million of common stock through December 31, 2028. No shares have been repurchased under this program as of the filing date.
-
B Medical Systems Divestiture Finalized
Azenta entered into a definitive Sale and Purchase Agreement on December 23, 2025, for the sale of its B Medical Systems business for $63 million, with the transaction expected to close on or before March 31, 2026.
-
Fiscal 2026 Guidance Reaffirmed
The company reiterated its full-year fiscal 2026 guidance, expecting total organic revenue growth in the range of 3% to 5% and Adjusted EBITDA margin expansion of approximately 300 basis points relative to fiscal 2025.
Analysis · AZTA · Technology
Azenta, Inc. reported mixed financial results for the first quarter of fiscal 2026, with organic revenue declining and non-GAAP profitability metrics (EPS, Adjusted EBITDA, gross margin) showing year-over-year decreases. However, the company reaffirmed its full-year fiscal 2026 guidance, signaling confidence in a stronger second half. Additionally, the board authorized a substantial $250 million share repurchase program, representing a significant commitment to shareholder returns. The definitive agreement for the sale of the B Medical Systems business provides strategic clarity and is expected to close by March 31, 2026, further streamlining the company's focus.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 29% of the 1635 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZTA was trading at $35.32 on NASDAQ in the Technology sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $23.91 to $55.64. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.